|
시장보고서
상품코드
2054639
축성 척추 관절염 시장 : 유형별, 치료법별, 투여 경로별, 제품 유형별, 성별, 유통 채널별, 최종사용자별, 지역별Axial Spondyloarthritis Market, By Type, By Therapeutics, By Route of Administration, By Product Type, By Gender, By Distribution Channel, By End User, By Geography |
||||||
축성 척추 관절염 시장은 2026년에 47억 2,000만 달러로 추계되고 있으며, 2033년까지 76억 1,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 7.0%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 47억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 7.00% | 2033년 시장 규모 예측 : | 76억 1,000만 달러 |
축성 척추관절염(axSpA)은 주로 척추 및 천장관절에 영향을 미치는 만성 염증성 류마티스 질환으로, 진행성 구조적 손상, 기능 장애 및 환자의 삶의 질(QOL)에 심각한 영향을 미치는 것이 특징입니다. 전 세계 축성 척추관절염 시장은 전 세계 수백만 명의 환자를 괴롭히는 이 중증 질환을 치료하기 위해 고안된 포괄적인 치료법, 진단 툴 및 관리 솔루션을 아우르고 있습니다. 이 범주에는 X선 소견을 동반하는 강직성 척추염(AS)과 X선 소견을 동반하지 않는 축성 척추관절염(nr-axSpA)이 모두 포함되어 있으며, 이는 질환의 분류 및 진행에 대한 이해의 진전을 반영하고 있습니다. 의료 종사자와 환자들의 인식이 높아진 데다, 조기 진단 및 표적 생물제제의 발전으로 인해 시장은 놀라운 성장세를 보이고 있습니다.
치료의 주류를 이루는 것은 종양괴사인자(TNF) 억제제, 인터류킨-17(IL-17) 억제제, 그리고 새롭게 등장한 야누키나제(JAK) 억제제이며, 이들은 환자에게 증상 관리의 개선과 질병 경과를 조절할 수 있는 가능성을 제공하고 있습니다. 헬스케어 분야의 의료비 증가, 자가면역 질환 유병률 상승, 첨단 영상 진단 기술에 따른 진단 능력 향상, 그리고 활발한 의약품 연구개발 활동이 맞물려 시장 확장을 주도하고 있으며, 전 세계 축성 척추관절염 시장은 더 광범위한 류마티스 치료제 업계에서 중요한 부문로서의 입지를 확고히 하고 있습니다.
시장 역학
전 세계 축성 척추관절염 시장은 시장 성장 전망과 치료법 발전의 기회를 종합적으로 높여주는 몇 가지 강력한 촉진요인에 힘입어 성장하고 있습니다. 특히 20-40세 젊은 성인층에서 이 질환의 유병률이 증가하는 것이 주요 성장 동력이 되고 있으며, 전 세계 인구의 약 0.7%가 축성 척추관절염(axSpA)을 앓고 있는 것으로 추정됨에 따라 효과적인 치료법에 대한 수요가 크게 증가하고 있습니다. 자기공명영상(MRI) 및 특수 바이오마커를 포함한 첨단 영상 진단 기술에 대한 인식이 높아지고 진단 능력이 향상됨에 따라 질환의 조기 발견과 조기 개입이 가능해졌으며, 치료가 가능한 환자층이 크게 확대되고 있습니다. 혁신적인 생물제제와 표적형 합성 질환 수정 항류마티스제(tsDMARDs)로 구성된 탄탄한 파이프라인은 치료 효과 향상과 맞춤형 치료 접근법을 제공하며, 프리미엄 가격 책정과 환자 예후 개선을 통해 시장 성장을 주도하고 있습니다.
그러나 시장 성장에는 뚜렷한 제약 요인도 존재합니다. 그 중 하나가 생물제제 치료에 따른 고액의 치료비입니다. 환자 1인당 연간 5만 달러를 초과하는 경우도 있으며, 가격에 민감한 시장에서 접근이 제한될 뿐만 아니라 전 세계 의료 시스템에서 보험 급여와 관련된 문제가 발생하고 있습니다. 또한 신약에 대한 엄격한 규제 승인 절차와 광범위한 임상 시험 요건이 맞물려 개발 기간이 길어지고 개발 비용이 증가하고 있으며, 이는 신흥 치료법의 시장 진입을 저해할 가능성이 있습니다. 또한 axSpA의 진단은 복잡한 특성을 지니고 있으며, 수년에 걸친 오진이나 진단 지연이 빈번하게 발생하므로, 적시 치료 시작과 시장 보급에 걸림돌이 되고 있습니다. 그럼에도 불구하고 개발도상국의 의료 인프라 확충, 의료비 증가, 그리고 브랜드 바이오의약품에 대한 비용 대비 효과가 높은 대안으로 떠오르는 바이오시밀러 의약품의 수용 확대를 통해 큰 기회가 창출되고 있습니다. 이를 통해 첨단 치료에 대한 접근성이 확대되고, 다양한 지역과 경제 계층에 걸쳐 시장 영향력이 확대될 가능성이 있습니다.
본 조사의 주요 특징
- 본 조사는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 축성 척추관절염 시장의 주요 기업을 분석하고 있습니다.
- 이 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계 축성 척추 관절염 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 축성 척추관절염 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 축성 척추 관절염 시장 : 유형별, 2021-2033년
제5장 세계의 축성 척추 관절염 시장 : 치료법별, 2021-2033년
제6장 세계의 축성 척추 관절염 시장 : 투여 경로별, 2021-2033년
제7장 세계의 축성 척추 관절염 시장 : 제품 유형별, 2021-2033년
제8장 세계의 축성 척추 관절염 시장 : 성별, 2021-2033년
제9장 세계의 축성 척추 관절염 시장 : 유통 채널별, 2021-2033년
제10장 세계의 축성 척추 관절염 시장 : 최종사용자별, 2021-2033년
제11장 세계의 축성 척추 관절염 시장 : 지역별, 2021-2033년
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 조사 방법
KSA 26.06.17Axial Spondyloarthritis Market is estimated to be valued at USD 4.72 Bn in 2026 and is expected to reach USD 7.61 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.00% | 2033 Value Projection: | USD 7.61 Bn |
Axial Spondyloarthritis (axSpA) represents a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints, characterized by progressive structural damage, functional impairment, and significant impact on patients' quality of life. The global axial spondyloarthritis market encompasses a comprehensive spectrum of therapeutic interventions, diagnostic tools, and management solutions designed to address this debilitating condition that affects millions worldwide. The market includes both ankylosing spondylitis (AS), the radiographic form, and non-radiographic axial spondyloarthritis (nr-axSpA), reflecting the evolving understanding of disease classification and progression. With increasing awareness among healthcare professionals and patients, coupled with advancements in early diagnosis and targeted biologics, the market has witnessed substantial growth momentum.
The therapeutic landscape is dominated by tumor necrosis factor (TNF) inhibitors, interleukin-17 (IL-17) inhibitors, and emerging Janus kinase (JAK) inhibitors, offering patients improved symptom management and disease modification potential. Rising healthcare expenditure, growing prevalence of autoimmune disorders, enhanced diagnostic capabilities through advanced imaging techniques, and robust pharmaceutical research and development activities are collectively driving market expansion, positioning the global axial spondyloarthritis market as a critical segment within the broader rheumatology therapeutics industry.
Market Dynamics
The global axial spondyloarthritis market is propelled by several compelling drivers that collectively enhance market growth prospects and therapeutic advancement opportunities. Increasing disease prevalence, particularly among young adults aged 20-40 years, serves as a primary growth catalyst, with an estimated 0.7% of the global population affected by axSpA, creating substantial demand for effective treatment solutions. Growing awareness and improved diagnostic capabilities through advanced imaging technologies, including magnetic resonance imaging (MRI) and specialized biomarkers, enable earlier disease detection and intervention, expanding the treatable patient population significantly. The robust pipeline of innovative biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) offers enhanced therapeutic efficacy and personalized treatment approaches, driving market expansion through premium pricing and improved patient outcomes.
However, market growth faces notable restraints including high treatment costs associated with biologic therapies, which can exceed USD 50,000 annually per patient, limiting accessibility in price-sensitive markets and creating reimbursement challenges for healthcare systems globally. Stringent regulatory approval processes for new therapeutic agents, coupled with extensive clinical trial requirements, result in prolonged development timelines and increased development costs, potentially hindering market entry for emerging treatments. Additionally, the complex nature of axSpA diagnosis, often involving years of misdiagnosis or delayed diagnosis, creates barriers to timely treatment initiation and market penetration. Nevertheless, significant opportunities emerge through expanding healthcare infrastructure in developing economies, increasing healthcare spending, and growing acceptance of biosimilar medications that offer cost-effective alternatives to branded biologics, potentially democratizing access to advanced treatments and expanding market reach across diverse geographic regions and economic segments.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global axial spondyloarthritis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AbbVie, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Novartis, Pfizer, Roche, UCB, Eli Lilly and Company, Merck & Co., Gilead Sciences, Sanofi, Takeda, Biogen, and Astellas Pharma
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global axial spondyloarthritis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global axial spondyloarthritis market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Ankylosing Spondylitis
- Non-radiographic Axial Spondyloarthritis
- Therapeutics Insights (Revenue, USD Bn, 2021 - 2033)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Meloxicam
- Naproxen
- Celecoxib
- Diclofenac
- Others (Indomethacin, etc.)
- Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
- TNF inhibitors
- Adalimumab
- Infliximab
- Etanercept
- Others (Golimumab, etc.)
- IL-17 inhibitors
- Secukinumab
- Ixekizumab
- Others (Bimekizumab, etc.)
- JAK inhibitors
- Tofacitinib
- Upadacitinib
- Conventional DMARDs
- Sulfasalazine
- Methotrexate
- Others (Corticosteroids, etc.)
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Subcutaneous (SC) Injections
- Intravenous (IV) Infusions
- Product Type Insights (Revenue, USD Bn, 2021 - 2033)
- Branded
- Generic
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Female
- Male
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Rehabilitation & physiotherapy centers
- Others (Academic and Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie
- Amgen
- Bristol-Myers Squibb
- Janssen Pharmaceuticals
- Novartis
- Pfizer
- Roche
- UCB
- Eli Lilly and Company
- Merck & Co.
- Gilead Sciences
- Sanofi
- Takeda
- Biogen
- Astellas Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Axial Spondyloarthritis Market, By Type
- Global Axial Spondyloarthritis Market, By Therapeutics
- Global Axial Spondyloarthritis Market, By Route of Administration
- Global Axial Spondyloarthritis Market, By Product Type
- Global Axial Spondyloarthritis Market, By Gender
- Global Axial Spondyloarthritis Market, By Distribution Channel
- Global Axial Spondyloarthritis Market, By End User
- Global Axial Spondyloarthritis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Axial Spondyloarthritis Market, By Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Non-radiographic Axial Spondyloarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Axial Spondyloarthritis Market, By Therapeutics, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Meloxicam
- Naproxen
- Celecoxib
- Diclofenac
- Others (Indomethacin, etc.)
- Meloxicam
- Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- TNF inhibitors
- Adalimumab
- Infliximab
- Etanercept
- Others (Golimumab, etc.)
- IL-17 inhibitors
- Secukinumab
- Ixekizumab
- Others (Bimekizumab, etc.)
- JAK inhibitors
- Tofacitinib
- Upadacitinib
- TNF inhibitors
- Conventional DMARDs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Sulfasalazine
- Methotrexate
- Sulfasalazine
- Others (Corticosteroids, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Axial Spondyloarthritis Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Subcutaneous (SC) Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intravenous (IV) Infusions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Axial Spondyloarthritis Market, By Product Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Axial Spondyloarthritis Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Axial Spondyloarthritis Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Axial Spondyloarthritis Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Rehabilitation & physiotherapy centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Axial Spondyloarthritis Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
